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Abstract
Objective
To explore changes in CSF sTREM2 concentrations in the evolving course of HIV-1 infection.
Methods
In this retrospective cross-sectional study, we measured concentrations of the macrophage/
microglial activation marker sTREM2 in CSF samples from 121 HIV-1–infected adults and 11
HIV-negative controls and examined their correlations with other CSF and blood biomarkers of
infection, inflammation, and neuronal injury.
Results
CSF sTREM2 increased with systemic and CNS HIV-1 disease severity, with the highest levels
found in patients with HIV-associated dementia (HAD). In untreated HIV-1–infected patients
without an HAD diagnosis, levels of CSF sTREM2 increased with decreasing CD4+ T-cell
counts. CSF concentrations of both sTREM2 and the neuronal injury marker neurofilament
light protein (NFL) were significantly associated with age. CSF sTREM2 levels were also
independently correlated with CSF NFL. Notably, this association was also observed in HIV-
negative controls with normal CSF NFL. HIV-infected patients on suppressive antiretroviral
treatment had CSF sTREM2 levels comparable to healthy controls.
Conclusions
Elevations in CSF sTREM2 levels, an indicator of macrophage/microglial activation, are
a common feature of untreated HIV-1 infection that increases with CD4+ T-cell loss and
reaches highest levels in HAD. The strong and independent association between CSF sTREM2
and CSF NFL suggests a linkage between microglial activation and neuronal injury in HIV-1
infection. CSF sTREM2 has the potential of being a useful biomarker of innate CNS immune
activation in different stages of untreated and treated HIV-1 infection.
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Despite expressing low levels of CD4,1,2 microglia and peri-
vascular macrophages in the CNS are important targets of
HIV-1 infection and likely key mediators of neuropathic in-
flammation and neuronal injury in HIV-1 infection, particu-
larly during its advanced phase. Microglia are the resident
myeloid cells in the CNS and are important components of
the local innate immune response to HIV-1 and may be
critical in the chronic immune activation characteristic of
CNS in untreated HIV-1.3 The chronic activation of microglia
and macrophages in HIV-1 together with possible microglial
dysfunction4 are probably involved in the pathogenesis of
HIV-associated neurocognitive disorders (HANDs) and
HIV-associated dementia (HAD).5
TREM2 is a receptor glycoprotein that belongs to the im-
munoglobulin superfamily. In the brain, TREM2 is expressed
exclusively by myeloid cells, including microglia and macro-
phages.6 In vitro, TREM2 promotes phagocytosis, suppresses
Toll-like receptor-induced inflammatory cytokine pro-
duction, and enhances anti-inflammatory cytokine transcrip-
tion.7 Its expression in the brain is upregulated in response to
the tissue damage that accumulates in aging and in neuro-
degenerative diseases.8 Increased CSF concentrations of sol-
uble TREM2 (sTREM2) have been noted in Alzheimer
disease9,10 and MS.11,12
The aim of this study was to explore changes in CSF sTREM2
through different stages of untreated and treatedHIV-1 infection
and to examine the relation of this microglial and macrophage
activation marker to changes in other markers of inflammation
and neuronal injury across a broad spectrum of HIV-1 infection.
Methods
Study design and patients
Archived blood and CSF samples from 121 HIV-infected adults
and 11 HIV-negative controls from Gothenburg, Sweden, and
San Francisco, CA, were analyzed in this retrospective cross-
sectional study. All samples were collected between 1999 and
2014 within the context of research protocols. Selection of
samples was performed to obtain a distribution of groups rep-
resenting progression of systemic HIV and the presentation of
overt neurologic disease and was not intended to reflect the
prevalence of treatment, systemic or CNS disease severity, or
treatment in the study sites.13 All participants were clinically
evaluated for neurologic and neurocognitive symptoms, but
formal neurocognitive testing was not routinely performed.
Participants were grouped as outlined in previous studies14,15: 4
groups of chronically HIV-infected patients without overt neu-
rologic complaints or signs, designated as “neuroasymptomatic”
(NA) and divided by blood CD4+ T-cell counts into 4 groups
with >350, 200–349, 50–199, andCD4< 50 cells/μL.The group
presenting with HAD was defined in accordance with the
Centers for Disease Control and Prevention and the American
Academy of Neurology Task force criteria.16,17 All these partic-
ipants were either antiretroviral treatment (ART) naive or off
treatment for at least 6 months when sampled. We also included
a group of treated HIV-infected patients with plasma HIV RNA
suppression to below 50 copies/mL for >1 year (ART sup-
pressed). A group of uninfected (HIV-negative) healthy controls
(n = 11) were included for comparison.
Standard protocol approvals and
patient consents
This study was approved by the institutional review boards of
the 2 study sites. All blood and CSF samples were analyzed
after obtaining informed consent of participants under these
institutional review board-approved protocols. If their ca-
pacity to provide consent was questioned, consent was also
obtained from those with power of attorney.
Blood and CSF sampling
Blood and CSF were obtained according to standard proto-
cols as previously described.18,19 CSF was immediately
centrifuged at low speed to remove cells and thereafter ali-
quoted and stored within 1 hour of collection at ≤−70°C until
the time of the biomarker assays. Blood was collected in
EDTA tubes, and plasma was aliquoted and stored in parallel
with CSF for later batch assays.
Laboratory methods
CSF sTREM2 was measured using an in-house electro-
chemiluminescence assay on a Meso Scale Discovery (MSD)
SECTOR imager 6000 (MSD, Rockville, MD), using
a method adapted from Kleinberger et al.20 The capture an-
tibody was biotinylated polyclonal goat anti-human TREM2
(0.25 μg/mL R&D Systems, Minneapolis, MN), and the de-
tector antibody was monoclonal mouse anti-human TREM2
(1 μg/Ml Santa Cruz Biotechnology, Dallas, TX). A standard
curve for calculations of unknowns was constructed using
recombinant human TREM2 (4,000–62.5 pg/mL), and CSF
samples were diluted 1:4 before being assayed. For a more
comprehensive description of the method, please see Alosco
et al.21 Intra-assay coefficients of variability were <15%, and all
samples were measured on the same day using the same
reagents.
Neopterin concentrations were analyzed in serum and CSF by
a commercially available immunoassay (BRAHMS, Hennigsdorf,
Germany), with an upper normal reference value of 8.8 nmol/L
in blood and 5.8 nmol/L in CSF.22
Glossary
HAD = HIV-associated dementia; HAND = HIV-associated neurocognitive disorder; IFN = interferon; MSD = Meso Scale
Discovery; NA = neuroasymptomatic; NFL = neurofilament light protein; WBC = white blood cell.
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CSF neurofilament light protein (NFL) concentrations were
measured by means of a sensitive sandwich assay (NF-light
ELISA kit; UmanDiagnostics AB, Umeå, Sweden) as pre-
viously described.15,23 CSF NFL was age adjusted to the study
population median of 42 years when comparing CSF NFL in
different study groups. The upper limit of normal was <773
ng/L, based on the antilog of the log scale mean + 2 SD in 359
healthy controls.24
The Cobas TaqMan RealTime HIV-1 (version 1 or 2;
Hoffmann-La Roche, Basel, Switzerland) and the Abbott
RealTime HIV-1 assay (Abbot Laboratories, Abbot Park, IL)
were used to measure HIV RNA levels in cell-free CSF and
plasma at each site. The study visits included assessments of
CSF white blood cell (WBC) count, CSF and blood albumin,
and blood CD4+ and CD8+ T lymphocyte counts by local
clinical laboratories using routine methods.
Statistical methods
Descriptive statistics were performed using Prism (version 7;
Graphpad Software Inc, La Jolla, CA) or SPSS (IBM SPSS
version 22) software. Continuous variables were log10 trans-
formed where appropriate to reduce skewness. Comparison
of biomarker concentrations was performed with one-way
analysis of variance and Tukey multiple comparison tests for
evaluation of multiple groups. Biomarker associations were
analyzed with Pearson correlation analysis. The relationship
between age log10 CSF sTREM2, NFL, and neopterin levels,
were analyzed with linear regression.
Data availability
The data sets analyzed during the current study are available
from the corresponding author on reasonable request.
Results
A total of 121 HIV-1–infected patients (49 women and 72
men) and 11 HIV-negative controls (4 women and 7 men)
were studied. Eighty-five of the included HIV-1–infected
patients were untreated and NA: 25 with CD4+ >350, 20 with
CD4+ 200–349, 20 with CD4+ 50–199, and 21 with CD4+
T-cell count <50 cells/μL; 7 additional untreated patients had
HAD (at the time categorized as AIDS dementia complex
using Memorial Sloan-Kettering Stage25 1, n = 4; stage 2, n =
2; and stage 3, n = 1); 28 patients were on suppressive stable
ART. The background clinical, laboratory, and demographic
data for each subject group are summarized in table 1.
Overall, the comparison of subgroups showed a significant
difference in CSF sTREM2 concentrations between the
groups (p < 0.001). The highest CSF sTREM2 levels were
found in patients with HAD, followed by untreated NA
patients with low CD4+ T-cell counts (figure 1, A). HIV-
infected patients on suppressive antiretroviral treatment had
CSF sTREM2 levels comparable to healthy controls. The
group with high CD4+ T-cell counts (>350 cells/μL) had the
lowest CSF sTREM2 concentrations among untreated NA
patients, and CSF sTREM2 increased gradually in groups
with lower blood CD4+ T-cell counts. Consequently, a re-
verse correlation was found betweenCSF sTREM2 andCD4+
T-cell count in NA patients (r = −0.32, p < 0.01). Similar
differences between the groups were also found in CSF
neopterin (figure 1, B) and CSF NFL (figure 1, C). Statistical
outcomes of group comparisons in these 3 biomarkers are
shown in table 2.
CSF sTREM2 showed a significant correlation with CSF
neopterin (r = 0.45, p < 0.0001) and CSF NFL (r = 0.62, p <
0.0001) in the full cohort. A correlation was also found be-
tween CSF neopterin and CSF NFL (r = 0.50, p < 0.0001),
figure 2, A–C. Figure e-1 (links.lww.com/NXI/A81) shows
a heat map of the Pearson correlation analysis that provides
a visual overview of the biomarker associations.
Age, CSF neopterin, and albumin ratio stood out as in-
dependent predictors of CSF sTREM2 in a multivariable
Table 1 Background characteristics
Groups N
Age Plasma HIV RNA CSF HIV RNA Blood CD4+ T cells
Median years (IQR) Median Log10 (IQR) Median Log10 (IQR) Median cells/mL (IQR)
HIV negative 11 39 (29–53) NA NA ND
Neuroasymtpomatic HIV (NA)
CD4 > 350 25 40 (30–47) 4.12 (3.54–4.64) 3.43 (2.41–4.13) 480 (395–705)
CD4 200–349 20 38 (31–45) 4.76 (4.32–5.31) 4.10 (3.44–4.52) 240 (212–285)
CD4 50–199 20 36 (32–50) 5.28 (4.65–5.64) 4.32 (3.77–4.91) 105 (62–148)
CD4 < 50 21 44 (35–48) 5.60 (5.08–5.90) 3.25 (2.13–3.76) 15 (10–30)
HAD 7 43 (42–62) 5.76 (5.23–5.96) 4.98 (4.14–5.45) 54 (31–80)
HIV, treated-suppressed (ART suppressed) 28 45 (34–58) <1.30 (<1.30–<1.30) <1.30 (<1.30–<1.30) 595 (452–862)
Abbreviations: HAD = HIV-associated dementia; IQR = interquartile range; NA = neuroasymtpomatic.
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Table 2 Comparisons of CSF sTREM2, neopterin, and NFL concentrations among groups
Group comparisons
CSF sTREM2
(log) CSF Neopterin (log)
CSF NFL
(log)
Overall ANOVA p
<0.001 <0.001 <0.001
Tukey multiple comparison
HAD vs HIV2 <0.001 a <0.001
HAD vs NA CD4 ≥ 350 <0.01 <0.001 <0.001
HAD vs NA CD4 200–349 ns ns <0.001
HAD vs NA CD4 50–199 ns ns <0.001
HAD vs NA CD4 < 50 ns ns <0.001
HAD vs ART suppressed <0.01 <0.001 <0.001
NA CD4 < 50 vs HIV2 <0.01 a <0.001
NA CD4 < 50 vs NA CD4 ≥ 350 <0.05 <0.001 <0.001
NA CD4 < 50 vs NA CD4 200–349 ns ns <0.001
NA CD4 < 50 vs NA CD4 50–199 ns ns ns
NA CD4 < 50 vs ART suppressed <0.05 <0.001 <0.001
NA CD4 50–199 vs HIV2 <0.05 a ns
NA CD4 50–199 vs NA CD4 ≥ 350 ns <0.01 ns
NA CD4 50–199 vs ART suppressed ns <0.001 <0.01
NA CD4 200–349 vs NA CD4 ≥ 350 ns <0.05 ns
NA CD4 200–349 vs ART suppressed ns <0.001 ns
NA CD4 ≥ 350 vs ART suppressed ns <0.01 ns
Abbreviations: ANOVA = analysis of variance; HAD = HIV-associated dementia; NA = neuroasymtpomatic; NFL = neurofilament light protein; ns = not
significant.
a CSF neopterin missing on HIV-negative participants.
Figure 1 Concentrations of CSF biomarkers in the 7 participant groups
The figure shows concentrations of CSF sTREM2 (A), CSF neopterin (B), and age-adjusted CSF NFL (C) in the 7 participant groups. Boxes in all panels
depict median and IQR, whiskers show 10–90 percentiles, and “+” designates the mean values. Gray horizontal lines show the upper limit of normal.
Statistical comparisons of groups are given in table 2. Measured markers are listed in the title of each panel and findings described in the text.
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analysis, including patients from all HIV groups, that included
CSF sTREM2 vs age, blood CD4+ T-cell count, CSF WBC,
albumin ratio, plasma and CSF HIV RNA, serum and CSF
neopterin, and ART (table 3).
CSF sTREM2 was confirmed as an independent predictor of
CSF NFL together with age, CD4+ T-cell count, and CSF
HIV RNA in a multiple linear regression analysis (table 3).
CSF sTREM2 and age
CSF sTREM2 and CSF NFL increased significantly with age
while no correlation between age and CSF neopterin was
found (figure 2, D–F).
When the 11 HIV-negative controls were exclusively evalu-
ated, a very strong correlation was found between CSF
sTREM2 and CSF NFL (r = 0.85, p < 0.01; figure 3, A),
although CSF NFL was within the normal range in all 11
controls. Both these CSF biomarkers increased with normal
aging (figure 3, B). Age and CSF sTREM2 stood out as in-
dependent predictors of CSF NFL in a multivariable analysis
(not shown). To be noted, neither CD4+ T cells nor neo-
pterin levels were available in the group of healthy controls.
Discussion
In this study, we found that CSF concentrations of sTREM2
increased with systemic HIV-1 disease progression as in-
dicated by blood CD4+ T-cell loss. High CSF sTREM2 levels
were generally found in patients with HAD. Microglia and
perivascular macrophages are important target cells for HIV-1
in the brain. In addition, these cells are also mediators of
inflammatory processes that may cause neuronal dysfunction
and injury as results of their activation. Microglial activation
is characteristic of and consistently found in HIV-1
encephalitis.26
We also found that CSF sTREM2 levels were strongly cor-
related with CSF concentrations of NFL. CSF NFL is typi-
cally markedly increased in HAD15 reflecting ongoing axonal
injury, something that was found also in the present study
(table e-1, links.lww.com/NXI/A82). However, compared
with nondemented patients with correspondingly high CSF
sTREM2 concentrations, patients with HAD had consider-
ably higher CSF NFL. A similar pattern was also found for
CSF neopterin. This may suggest that macrophage and micro-
glial activation is not enough to cause neurodegeneration in
HAD but that also other mechanisms than immune activation
probably are involved in the pathogenesis.
ART has had a profound effect on morbidity and mortality of
HIV-1 infection, including HAD and other complications in-
volving the CNS.27 However, while substantially reduced by
ART, residual CNS immune activation has been found in al-
most half of the patients with durably suppressed plasma and
CSF virus.28 In the present study, 36% of patients on suppres-
sive ART still had CSF neopterin levels above the upper normal
reference limit. However, no significant difference in CSF
sTREM2 between ART-treated HIV-1–infected patients and
HIV-negative controls was found in this study. This may suggest
that the persistent CNS immune activation that is commonly
Figure 2 Correlations between CSF biomarkers and age
The figure shows correlations between CSF sTREM2, neopterin, and NFL (A–C). Regression lines and Pearson correlation coefficient are shown in each panel.
Associations between CSF biomarkers and age (D–F). Regression lines and Pearson correlation coefficient are shown in panel D and F. No significant
correlation was found between CSF neopterin and age (E). NFL = neurofilament light protein.
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found in patients on effective ART is not mainly driven by
macrophage/microglial activation, but rather by activated
lymphocytes or astrocytes. The pteridine metabolite neopterin
has been extensively studied in HIV. Increased CSF levels are
generally found in untreated HIV22 and can also, as previously
mentioned, often be found in patients on ART5,28 and are
slightly higher in ART-treated non-HAD patients with milder
forms of HAND compared with unimpaired patients.5 Neo-
pterin is produced primarily in monocytes/macrophages and
related cells, and the most important stimuli are interferons
Table 3 Univariable correlation (left columns) and multiple linear regression (right columns) determining predictors of
log10 CSF sTREM2 and log10 CSF NFL
Predictor
Univariable Multivariable
Std b (r) p Std badj p
Predicting CSF sTREM2
Age 0.504 <0.001 0.384 <0.001
CD4 −0.356 <0.001
CSF WBC 0.008 0.931
CSF/P albumin ratio 0.492 <0.001 0.297 <0.001
P HIV RNA 0.344 <0.001
CSF HIV RNA 0.295 0.001
S neopterin 0.409 <0.001
CSF neopterin 0.454 <0.001 0.385 <0.001
ART −0.204 0.024
Predicting CSF NFL
Age 0.406 <0.001 0.300 0.001
CD4 −0.536 <0.001 −0.384 <0.001
CSF WBC −0.064 0.489
CSF/P albumin ratio 0.413 <0.001
CSF HIV RNA 0.351 <0.001 0.184 0.017
CSF neopterin 0.498 <0.001
CSF sTREM2 0.897 <0.001 0.258 0.003
ART −0.276 0.002
Abbreviations: NFL = neurofilament light protein; WBC = white blood cell.
Figure 3 CSF sTREM2 in HIV-negative controls
(A) A strong correlation between CSF
sTREM2 and CSF NFL was found in HIV-
negative controls (n = 11). (B) Both CSF
sTREM2 and NFL increase with age in
healthy controls. NFL = neurofilament
light protein.
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(IFNs), especially Th1-type cytokine IFN-γ.29 However,
astrocytes can also produce neopterin on activation,30 and CSF
concentrations of neopterin can probably increase also during
lymphocytic inflammation, as seen in, for example, early HIV-1
infection with aseptic meningitis.
TREM2 is an innate immune receptor expressed exclusively
on the surface of cells of the monocytic lineage. It is a type-1
transmembrane glycoprotein with an ectodomain that is
proteolytically cleaved and released into the extracellular
space as a soluble variant (sTREM2), making sTREM2
a more specific biomarker of macrophage/microglial activity
than neopterin. The process whereby sTREM2 is released
into the extracellular space and the CSF is also different
compared with the mechanisms that are driving neopterin
production, which may contribute to different expressions of
these 2 biomarkers. CSF sTREM2 may be a later and there-
fore less sensitive marker of macrophage/microglial activation
than neopterin, thereby requiring larger numbers of study
participants to disclose possible differences between the
groups, an assumption that may be supported by the fact that
we could not demonstrate any difference between HIV neg-
atives and ART-treated study participants in CSF NFL either,
although a small but significant difference has been found in
previous larger studies.15,31 CSF neopterin was not available
in HIV-negative controls in the present study.
Brain imaging using PET has been studied as an in vivo
method to reveal microglial activation,32,33 but it may not be
sensitive enough in HIV, at least when the translocator pro-
tein (TSPO) ligand is used.34 PET scanning is also expensive
and not generally available, and it would be beneficial to
identify a reliable CSF biomarker of macrophage/microglial
activation in HIV. Such a marker could facilitate studies ex-
ploring pathogenesis of neuro-HIV in untreated and treated
HIV-infected patients and potentially also employ a clinical
usage in treated patients with cognitive impairment.
Other markers of microglial activation that have been sug-
gested for studies in HIV are sCD163, sCD14, Monocyte
chemoattractant protein-1 (MCP-1), Chitinase-3-like protein
1 (YKL-40), and ganglioside GD3.3,35–38 However, most of
those are not sufficiently specific for microglial and macro-
phage activation. sTREM2, the secreted form of the triggering
receptor, is exclusively expressed on myeloid cells but not on
astrocytes and therefore has the potential to become a CSF
biomarker selective for macrophage/microglial activation.
Of interests, a strong correlation between CSF sTREM2 and
CSF NFL levels was also found in HIV-negative controls with
normal CSF NFL in relation to their age. The brain displays
an increasing inflammatory state with aging, and both
microglial dysfunction and neuronal injury increase with
normal aging.39 Age-related microglial activation coincides
with age-related neurodegeneration and cognitive decline,40
and the results from our small cohort of HIV-negative con-
trols support a linkage between microglial activation and
axonal injury in normal aging. This is a research area of great
interest that needs to be further explored.
This study has several limitations. Although the total number
of participants was reasonably large, some of the groups were
limited in size, especially the HAD group because of its low
incidence. We used a cross-sectional design to reconstruct
a longitudinal process. It has become increasingly difficult to
perform longitudinal studies on untreated patients when early
and universal ART is standard. Neurocognitive performance
testing was not consistently performed in non-HAD patients,
precluding examination of associations of CSF sTREM2 level
elevations with milder forms of HAND. Although TREM2 is
exclusively expressed by myeloid cells, CSF sTREM2 levels
cannot distinguish between microglial and macrophage acti-
vation. The various contributions of these cells to the CNS
immune activation and pathogenesis in HIV-1 disease have
not been established and also cannot be determined by the
results of this study.
Macrophage/microglial activation, as measured by CSF
sTREM2, increased with decreasing CD4+ T-cell counts in
NA HIV and was especially high in HAD. The magnitude of
the increase in CSF sTREM2 levels in HAD relative to healthy
controls was similar to that previously noted in Alzheimer
disease and MS.10,12 Both CSF sTREM2 and CSF NFL in-
crease with normal aging, but there is also a strong in-
dependent association between CSF sTREM2 and axonal
injury as measured by CSF NFL. Of interest, this is also the
case in healthy controls. Our results suggest that CSF
sTREM2 is a potentially useful biomarker of microglial acti-
vation in different stages of HIV infection.
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